{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T04:14:49Z","timestamp":1746159289800,"version":"3.40.4"},"reference-count":12,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.antiviral.2014.01.019","type":"journal-article","created":{"date-parts":[[2014,2,2]],"date-time":"2014-02-02T11:31:18Z","timestamp":1391340678000},"page":"59-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Efficacy and tolerability after 24weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV\u2013HCV coinfected subjects"],"prefix":"10.1016","volume":"104","author":[{"given":"Miguel","family":"Genebat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Hern\u00e1ndez-Quero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"Guardiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onofre","family":"Mart\u00ednez-Madrid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Garc\u00eda","family":"de la Llana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"S\u00e1nchez-Villegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hortensia","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 F.","family":"Lluch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda A.","family":"Mart\u00ednez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezequiel","family":"Ruiz-Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.01.019_b0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2014.01.019_b0010","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC) \u2013 NCT01514890","volume":"59","author":"H\u00e9zode","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.019_b0015","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.019_b0020","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/QAD.0b013e32836138d0","article-title":"Efficacy and tolerance of telaprevir in HIV\u2013hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results","volume":"27","author":"Lacombe","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2014.01.019_b0025","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.019_b0030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jhep.2012.12.023","article-title":"Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure","volume":"58","author":"Pol","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.019_b0035","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.019_b0040","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/QAD.0b013e32833a0918","article-title":"Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study","volume":"24","author":"Smith","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2014.01.019_b0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","article-title":"Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial","volume":"159","author":"Sulkowski","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2014.01.019_b0050","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.019_b0055","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2012.12.026","article-title":"Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997","volume":"144","author":"van der Helm","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.01.019_b0060","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N. Engl. J. Med."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421400031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421400031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T19:04:39Z","timestamp":1746126279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421400031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":12,"alternative-id":["S016635421400031X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.019","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability after 24weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV\u2013HCV coinfected subjects","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}